Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Participants With Selected Relapsed/Refractory GPNMB-Expressing Solid Tumours

NCT07297667 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT07297667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Participants With Selected Relapsed/Refractory GPNMB-Expressing Solid Tumours
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 1
Overall status
Recruiting
Start date
August 30, 2026
Completion date
September 1, 2033
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar soft part sarcoma, renal cell carcinoma, triple negative breast cancer